More than 550 Global Clinical Research Sites Share their Capabilities, Attitudes and Expectations for Technology Systems in the 2015 DrugDev Site Survey

Share Article

Results of wide-reaching global survey published in DIA Global Forum highlight the rising demand for technology-based solutions to enable sites to do more clinical trials

News Image
The survey responses contain insights into the level of communication, effort and investment needed by sponsors, CROs and sites to achieve mainstream adoption of clinical technologies.

Clinical trial investigators worldwide want technologies that make it faster, easier and less expensive to find patients and conduct clinical trials, reports an annual survey conducted by DrugDev. 572 investigators from nine countries (Argentina, Australia, Brazil, France, Germany, India, South Africa, the United Kingdom and the United States) provided detailed answers regarding the current use and future expectations for clinical technologies. Results were published in the October issue of the DIA Global Forum. Click here to read the entire report.

Highlights from the survey:

  •     Globally, 80% of investigators reported that all staff had access to a computer for clinical data collection though WiFi was available in exam rooms for less than 80% of sites.
  •     Sites most frequently use a desktop computer for data collection (85%); use of mobile/tablets was significantly lower (<15%).
  •     Investigators rated e-signature as the technological advancement most likely to become Gold Standard in the next 3 years and offer a decrease in investigator burden.
  •     Use of electronic medical records (EMR) varied greatly between countries (21% in South Africa, to 67% in the US). The market for EMR systems was extremely fragmented, thus posing potential challenges for consistent use of EMR in clinical operations.

Survey co-authors Elisa Cascade, President of DrugDev Data Solutions, and Claire Sears PhD, DrugDev Director of Investigator Engagement, report, “Adopting new technology is crucial if the pharmaceutical industry is to make measurable improvements in speeding study start-up, streamlining clinical trial data transmission, and overhauling how studies are monitored, but it also is crucial that sites are seen as partners in the development and implementation of new trial technology.”

The survey responses contain insights into the level of communication, effort and investment needed by sponsors, CROs and sites to achieve mainstream adoption of clinical technologies.

In addition to DIA Global Forum, leading pharma industry magazines have written about the DrugDev Site Survey, including:

To learn more about how DrugDev helps sites do more trials, visit http://www.drugdev.com.

About DrugDev
DrugDev enables sponsors, CROs and sites to Do More Trials through industry-wide collaboration, standardization and a beautiful technology experience. Built around the largest global network of active opted-in investigators, DrugDev’s unified solutions suite optimizes site selection and startup, investigator payments and clinical operations. DrugDev also serves as the trusted third-party host of the revolutionary Investigator Databank collaboration and powers the TransCelerate Investigator Registry (launching this year). Learn why 9 of the top 10 sponsors and 4 of the top 5 CROs rely on DrugDev technology to do more trials at drugdev.com – and connect with DrugDev on LinkedIn and Twitter to join the conversation.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Brenda Nashawaty
DrugDev
+1 617-688-3253
Email >

Kristopher Sarajian
DrugDev
617-952-4071 132
Email >
@drugdevinc
Follow >
Visit website